



Premier Manufacturer & Wholesaler of Health, Wellness & Peak Performance Nutraceuticals & Nootropics

Key Stats



Table with 2 columns: Metric and Value. Rows include Stock Price, 52-Wk Low-high, Shares Outstanding, Market Cap, Avg. Daily Vol, Insider Holdings, Public Float, Revenue, Cash & Equiv, and Employees.

Experienced Management



Michael Hill, CEO & Chairman: 20+ years' executive experience with private & public companies.



Barrett Evans, President and CSO: 30+ years' experience in private /public company investment and finance.



Doug Rohrer, CBO: 20+ years' senior banking, law & operational experience for several companies, including start-ups.

Company Contacts

Bloomios, Inc. Santa Barbara, CA
Bloomios.com • Tel (805) 222-6330
Doug Rohrer, Chief Business Officer
info@bloomios.com • Tel (805) 222-6467

CMA Investor, Media & Public Relations
Ron Both (IR) & Tim Randall (PR)
BLMS@cma.team • Tel (949) 432.7566

Hybrid Financial
info@hybridfinancial.ca • Tel (416) 479-8168
hybridfinancial.com

Overview

About Bloomios

Manufacturer of hemp-derived cannabinoid & mushroom edibles, cosmetic & topical sports products, nootropics and adjacent wellness supplements.

Branded, white & private label solutions: full-service R&D, branding, product development and manufacturing for in-house & 3rd party brands & wholesalers.

Organic & Acquisitive Growth Strategy: Adding native (owned) brands for wholesale & DTC channels and expanding product mix. Pursuing acquisitions to add order flow, production capacity and distribution channels.

Recent Transformative Acquisition

- Acquired CBD Infusionz Q4-22 for \$23.5M.
Highly-accretive: added \$22M in revenue and \$4.4M adj. EBITDA TTM at 6/30/22, vs. existing organic TTM of \$6.7M.
Added IP portfolio of new products, formulations and flavors.
Doubled manufacturing capacity.

Large, Fast-growing Markets

N. American Cannabinoid market: 33.3% CAGR to \$61.3 billion by 2027.1

Global Nootropics market: 13.9% CAGR to \$30 billion by 2029.2

Global CBD skincare market: 24.8% CAGR to \$3.5 billion by 2026.3

Recent News Highlights

3/27/23: Appointed industry veteran, Joe Reid, as chief manufacturing officer.

10/27/22: Completed \$23.5M acquisition of leading gummy manufacturer.

8/4/22: Engaged by 3rd party brands to develop new line of private-label consumer health and wellness products.

5/18/22: Completed expansion of production capacity by 300%.


State-of-the Art Manufacturing Facility



Full Range of Customizable Products


Consumables

Gummies: 84 SKUs, Tinctures: 24 SKUs, MSRP \$3.99 - \$250




Topicals

37 SKUs, MSRP \$4.99 - \$59.99




Pet

22 SKUs, MSRP \$19.99 - \$49.99



High-Growth Opportunity

N. America Cannabinoid Market1



Footnotes: 1) Graphical Research, May 2021; 2) Databridge Market Research April 2022; 3) Allied Market Research, Dec. 2021. Important Disclaimer: This document includes forward looking statements that involves risk and uncertainties as described in the Bloomios, Inc's filings with the U.S. Securities and Exchange Commission and available on sec.gov. This document does not constitute an offer to sell, or a solicitation of an offer to buy, any security. Bloomios makes no guarantee as to the reliability or timeliness of this information; you should not rely on it as the basis for any investment decision. © Bloomios, Inc 2023. All Rights Reserved. Product of CMA. 032723